Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Surg Oncol. 2016 Mar;42(3):333-42. doi: 10.1016/j.ejso.2015.10.015. Epub 2015 Nov 23.

Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?

Author information

1
Breast Unit of the Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Belgium. Electronic address: peter.vandam@telenet.be.
2
Centre of Oncologic Research (CORE), Antwerp University, Edegem, Belgium.
3
Breast Unit of the Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Belgium.
4
Breast Unit of the Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Belgium; Fase 1 Unit for Experimental Oncology, Antwerp University Hospital, Belgium.

Abstract

During the last decade neoadjuvant endocrine therapy (NET) has moved from being reserved for elderly and frail non-chemotherapy candidates to a primary systemic modality in selected patients with hormone sensitive breast cancer. Neoadjuvant hormonal treatment in patients with hormone receptor positive, HER-2 negative early breast cancer is proven to be an effective and safe option; it is associated with a higher rate of breast conserving surgery (BCS), may reduce the need for adjuvant chemotherapy and enables a delay of surgery for medical or practical reasons. Clinical responses range from 13% to 100% with at least 3 months of NET. Methods of assessing response should include MRI of the breast, particularly in lobular tumours. In studies comparing tamoxifen with aromatase inhibitors (AI), AI proved to be superior in terms of tumour response and rates of BCS. Change in Ki67 is accepted as a validated endpoint for comparing endocrine neoadjuvant agents. Levels of Ki67 during treatment are more closely related to long-term prognosis than pretreatment Ki67. Neoadjuvant endocrine therapy provides a unique opportunity for studies of endocrine responsiveness and the development of new experimental drugs combined with systemic hormonal treatment.

KEYWORDS:

Aromatase inhibitors; Breast cancer; Fulvestrant; Neoadjuvant treatment; Oestrogen receptor positive; Tamoxifen

PMID:
26776766
DOI:
10.1016/j.ejso.2015.10.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center